insights_auto
Zakaj je tečaj GIS zrasel 2,45%?
Podrobneje raziščichevron_right
GIS:FRA
Gilead Sciences, Inc
154,04 €
arrow_upward
+2,45%(+3,68) 1D
20. nov., 15:25:14 GMT +1 · EUR
search
Vsi simboli
| Simbol | Cena | Sprememba | Odstotna sprememba |
|---|
insights_autoGeneriranje najpomembnejših vpogledov za GIS …
Odpri
152,16 €
Visoka
154,04 €
Nizka
152,16 €
Tržna kapitalizacija
209,85 mrd.
Povprečni promet
276,00
Promet
690,00
52-tedenski najvišji tečaj
157,14 €
52-tedenski najnižji tečaj
100,42 €
Št. zaposlenih
17 tis.
Odpri
152,16 €
Visoka
154,04 €
Nizka
152,16 €
Tržna kapitalizacija
209,85 mrd.
Povprečni promet
276,00
Promet
690,00
52-tedenski najvišji tečaj
157,14 €
52-tedenski najnižji tečaj
100,42 €
Št. zaposlenih
17 tis.
Novice
Iz spletnih virov in novičarskih partnerjev
MarketWatch
·
pred 17 urami
Gilead Sciences Inc. stock outperforms competitors despite losses on the day
ad-hoc-news.de
·
pred 23 urami
Gilead Sciences stock: HIV growth faces Biktarvy pricing risk
Quantisnow
·
pred 2 dnevoma
Gilead Sciences (GILD) executive Mercier sold 28,000 shares for $4.78M at an average $170.55 under a 10b5-1 plan
Investing.com
·
pred 2 dnevoma
Gilead at Jefferies Global Healthcare Conference: growth broadens
Profil
Gilead Sciences, Inc. is an American biopharmaceutical company headquartered in Foster City, California, that focuses on researching and developing antiviral drugs used in the treatment of HIV/AIDS, hepatitis B, hepatitis C, influenza, and COVID-19. It also develops medicines in therapeutic areas such as oncology and inflammation and cell therapy.
In 1987, Michael L. Riordan founded the company under the name Oligogen. The original name was a reference to oligonucleotides, small strands of DNA used to target genetic sequences. Gilead held its initial public offering in 1992, and successfully developed drugs including Tamiflu and Vistide that decade.
In the 2000s, Gilead began evolving from a biotechnology company into a large pharmaceutical company, through acquisitions and investments, acquiring several subsidiaries. Gilead is a member of the Nasdaq-100 and the S&P 100.
The company has faced criticism over its business practices, including extremely high pricing of drugs such as Sovaldi and Truvada in the United States relative to production cost and cost in the developing world. Wikipedia
Vizitka: Gilead Sciences, Inc
Generalni direktorDaniel O'Day
Št. zaposlenih17 tis.
Ustanovljeno22. jun. 1987
SedežFoster City, Kalifornija, Združene države Amerike
SektorHealth Care
Panoga-
Spletno mestogilead.com